dexelvucitabine
Small moleculeexperimental
Dexelvucitabine is a failed experimental agent for the management of human immunodeficiency virus infection. It is a cytidine nucleoside analog and nucleoside reverse transcriptase inhibitor. that inhibits HIV-1 replication in vitro. During phase II clinical trials there was some indication of a decreased mean viral load in patients with infected human immunodeficiency virus. — Wikipedia
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jun 24, 2002 (NCT00040274)
Timeline
Indications
Studied for
Mechanism of action
- Hepatitis B virusINHIBITOR
Hepatitis B virus inhibitor
- Human immunodeficiency virusINHIBITOR
Human immunodeficiency virus inhibitor
Human immunodeficiency virus type 1 reverse transcriptase inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Nc1nc(=O)n([C@H]2C=C[C@@H](CO)O2)cc1F- Mol. weight
- 227.19 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaDexelvucitabine ↗
- ChEMBLCHEMBL109831 ↗
Also known as
- 2(1h)-pyrimidinone, 4-amino-1-((2s,5r)-2,5-dihydro-5-(hydroxymethyl)-2-furanyl)-5-fluoro-
- 2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine
- 2',3'-dideoxy-2',3'-didehydro-beta-d-5-fluorocytidine
- 2',3'-dideoxy-2',3'-didehydro-beta-l-5-fluorocytidine
- 4-amino-5-fluoro-1-((2s,5r)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl)pyrimidin-2(1h)-one
- dexelvucitabine
- dexelvucitabine
- dexelvucitabine
- dexelvucitabine
- dexelvucitabine
- dpc817
- dpc 817
- dpc 817
- dpc 817
- dpc-817
- dpc-817
- dpc-817
- incb-8721
- incb-8721
- incb-8721
- reverset
- reverset
- reverset
- yz-817
- yz-817
- yz-817
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00300573 | Phase 2 | Apr 1, 2006 | Incyte |
| NCT00040274 | Phase 1 | Jun 24, 2002 | Pharmasset |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Incyte | For profit | 1 | 1 | 1 | 2006 |
| Pharmasset | For profit | 1 | 1 | 1 | 2002 |
2 organizations
Page 1 / 1